158 related articles for article (PubMed ID: 24155058)
1. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
Kakuda TN; Woodfall B; De Marez T; Peeters M; Vandermeulen K; Aharchi F; Hoetelmans RM
J Antimicrob Chemother; 2014 Mar; 69(3):728-34. PubMed ID: 24155058
[TBL] [Abstract][Full Text] [Related]
2. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
[TBL] [Abstract][Full Text] [Related]
3. Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
Schöller-Gyüre M; Kakuda TN; Witek J; Akuma SH; De Smedt G; Spittaels K; Vyncke V; Hoetelmans RM
J Clin Pharmacol; 2013 Feb; 53(2):202-10. PubMed ID: 23436265
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.
Kakuda TN; Leopold L; Nijs S; Vandevoorde A; Crauwels HM; Bertelsen KM; Stevens M; Witek J; van Delft Y; Tomaka F; Hoetelmans RM
J Clin Pharmacol; 2014 May; 54(5):563-73. PubMed ID: 25975423
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Kakuda TN; DeMasi R; van Delft Y; Mohammed P
HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
[TBL] [Abstract][Full Text] [Related]
7. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
8. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
Kakuda TN; Schöller-Gyüre M; Workman C; Arasteh K; Pozniak AL; De Smedt G; Beets G; Peeters M; Vandermeulen K; Woodfall BJ; Hoetelmans RM
Antivir Ther; 2008; 13(5):655-61. PubMed ID: 18771049
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
Kakuda TN; Schöller-Gyüre M; De Smedt G; Beets G; Aharchi F; Peeters MP; Vandermeulen K; Woodfall BJ; Hoetelmans RM
HIV Med; 2009 Mar; 10(3):173-81. PubMed ID: 19207601
[TBL] [Abstract][Full Text] [Related]
10. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
11. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers.
Apseloff G; Foulds G; LaBoy-Goral L; Willavize S; Vincent J
J Clin Pharmacol; 1998 Sep; 38(9):830-5. PubMed ID: 9753212
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
Schöller-Gyüre M; Kakuda TN; Sekar V; Woodfall B; De Smedt G; Lefebvre E; Peeters M; Hoetelmans RM
Antivir Ther; 2007; 12(5):789-96. PubMed ID: 17713162
[TBL] [Abstract][Full Text] [Related]
13. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
Schöller-Gyüre M; Boffito M; Pozniak AL; Leemans R; Kakuda TN; Woodfall B; Vyncke V; Peeters M; Vandermeulen K; Hoetelmans RM
Pharmacotherapy; 2008 Oct; 28(10):1215-22. PubMed ID: 18823217
[TBL] [Abstract][Full Text] [Related]
14. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
Kakuda TN; Van Solingen-Ristea RM; Onkelinx J; Stevens T; Aharchi F; De Smedt G; Peeters M; Leopold L; Hoetelmans RM
J Clin Pharmacol; 2014 Apr; 54(4):422-31. PubMed ID: 24165884
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.
Kakuda TN; Schöller-Gyüre M; Hoetelmans RM
Clin Pharmacokinet; 2011 Jan; 50(1):25-39. PubMed ID: 21142266
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
[TBL] [Abstract][Full Text] [Related]
17. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents.
Königs C; Feiterna-Sperling C; Esposito S; Viscoli C; Rosso R; Kakuda TN; Leemans R; Peeters M; Mack R; Peeters I; Sinha R; Boven K; Giaquinto C
AIDS; 2012 Feb; 26(4):447-55. PubMed ID: 22156961
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.
Boffito M; Jackson A; Lamorde M; Back D; Watson V; Taylor J; Waters L; Asboe D; Gazzard B; Pozniak A
J Acquir Immune Defic Syndr; 2009 Oct; 52(2):222-7. PubMed ID: 19620877
[TBL] [Abstract][Full Text] [Related]
20. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.
Hafner R; Bethel J; Power M; Landry B; Banach M; Mole L; Standiford HC; Follansbee S; Kumar P; Raasch R; Cohn D; Mushatt D; Drusano G
Antimicrob Agents Chemother; 1998 Mar; 42(3):631-9. PubMed ID: 9517944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
